Targeting Dxr/IspC to develop drugs against malaria and tuberculosis

Targeting Bacterial Persistence to Develop Therapeutics Against Infectious Disease

Prospects for vaccines to protect against AIDS, tuberculosis, and malaria.

Given the scope of the worldwide health problems caused by the acquired immunodeficiency syndrome, tuberculosis, and malaria, it is imperative that vaccines be developed to prevent these infections. Recent advances in the understanding of these diseases suggest that T-lymphocyte-mediated immunity is important in containing these infections. The application of novel vaccine technologies for elic...

Spatial targeting of interventions against malaria.

Malaria transmission is strongly associated with location. This association has two main features. First, the disease is focused around specific mosquito breeding sites and can normally be transmitted only within certain distances from them: in Africa these are typically between a few hundred metres and a kilometre and rarely exceed 2-3 kilometres. Second, there is a marked clustering of person...

An Approach to the Search for New Drugs Against Tuberculosis

The history of Mycobacterium tuberculosis (MTB) as the main agent of tuberculosis (TB) goes back a very long time. Fragments of the spinal column of Egyptian mummies from 2400 BCE (Before Common Era) show definite pathological signs of tubercular decay (Tripathi, Tewari et al., 2005). From that time to the present day millions have died of the disease and only a few drugs are active against the...

Novel drugs against tuberculosis: a clinician's perspective.

The United Nations Millennium Development Goal of reversing the global spread of tuberculosis by 2015 has been offset by the rampant re-emergence of drug-resistant tuberculosis, in particular fluoroquinolone-resistant multidrug-resistant and extensively drug-resistant tuberculosis. After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have bee...